| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Piotr Jahołkowski, Julita Niewiadomska, Jacek Wciórka, Mirosław Kowalski, Piotr Świta. Clozapine-induced myocarditis during co-administration of valproate: A case report. Psychiatria polska. vol 53. issue 5. 2020-09-16. PMID:31955181. |
in this paper, we present a case of a 22-year-old male patient with refractory schizophrenia who developed cimduring low-dose clozapine treatment with co-administration of valproate and risperidone. |
2020-09-16 |
2023-08-13 |
Not clear |
| Teruki Koizumi, Takefumi Suzuki, Nikhil Sasidharan Pillai, Robert R Bies, Hiroyoshi Takeuchi, Kimio Yoshimura, Masaru Mimura, Hiroyuki Uchid. Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. Journal of psychiatric research. vol 117. 2020-09-14. PMID:31254838. |
patients with schizophrenia (icd-10) who reported having auditory hallucination, receiving monotherapy with risperidone, olanzapine or paliperidone for at least two weeks were included. |
2020-09-14 |
2023-08-13 |
human |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
an open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes. |
2020-08-17 |
2023-08-13 |
Not clear |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
this study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (fes). |
2020-08-17 |
2023-08-13 |
Not clear |
| Sung Woo Joo, Seung-Hyun Shon, GumJee Choi, MinJung Koh, Seung Woo Cho, Jungsun Le. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 9. 2020-08-07. PMID:31362852. |
patients with schizophrenia in the south korea health insurance review agency database from 2007 to 2016 who had received lai haloperidol, lai paliperidone, or lai risperidone were included. |
2020-08-07 |
2023-08-13 |
Not clear |
| Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang, Richa Bashya. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Current medical research and opinion. vol 35. issue 12. 2020-07-10. PMID:31366251. |
transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among veterans health administration patients with schizophrenia who have had at least one prior hospitalization. |
2020-07-10 |
2023-08-13 |
Not clear |
| Daniela Petrić, Valentino Rački, Nadija Gačo, Ana Kaštelan, Mirjana Graova. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. Journal of child and adolescent psychopharmacology. vol 29. issue 3. 2020-06-29. PMID:30758986. |
the aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone. |
2020-06-29 |
2023-08-13 |
Not clear |
| Jacob Spertus, Marcela Horvitz-Lennon, Sharon-Lise T Norman. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. Medical decision making : an international journal of the Society for Medical Decision Making. vol 39. issue 5. 2020-04-20. PMID:31375050. |
in an application, we examine the risk of excessive weight gain for patients with schizophrenia treated with the second-generation antipsychotics paliperidone, risperidone, or olanzapine in 14 clinical trials. |
2020-04-20 |
2023-08-13 |
human |
| Ziqiao Feng, Yunqiao Zhang, Xu You, Wenyu Zhang, Yuhan Ma, Qing Long, Zijun Liu, Wei Hao, Yong Zeng, Zhaowei Ten. Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. Medicine. vol 99. issue 15. 2020-04-20. PMID:32282724. |
effects of risperidone on blood levels of interleukin-6 in schizophrenia: a meta-analysis. |
2020-04-20 |
2023-08-13 |
Not clear |
| Stefan Leucht, Ágota Barabássy, István Laszlovszky, Balázs Szatmári, Károly Acsai, Erzsébet Szalai, Judit Harsányi, Willie Earley, György Német. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 9. 2020-03-17. PMID:30836381. |
we conducted post hoc equipercentile linking analyses of positive and negative syndrome scale (panss) outcomes (e.g., panss-factor score for negative symptoms [fsns]) with clinical global impressions-improvement (cgi-i) and -severity (cgi-s) ratings on data from patients treated with cariprazine (n = 227) or risperidone (n = 229) in a clinical study evaluating negative symptoms in schizophrenia. |
2020-03-17 |
2023-08-13 |
Not clear |
| Simon Gilbody, Anne-Marie Bagnall, Lorna Duggan, Arja Tuunaine. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. The Cochrane database of systematic reviews. vol 9. 2020-02-25. PMID:27648956. |
withdrawn: risperidone versus other atypical antipsychotic medication for schizophrenia. |
2020-02-25 |
2023-08-13 |
Not clear |
| Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringshei. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2020-02-25. PMID:29758999. |
we conducted meta-analyses of randomised controlled trials included in the cochrane database of systematic reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with sgas (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, l-sulpiride, and ziprasidone) approved in canada and the uk, comparing them with haloperidol and chlorpromazine. |
2020-02-25 |
2023-08-13 |
Not clear |
| Ajita S Nayak, Heena H Merchant, Hrishikesh B Nachane, Aditya R Anveka. Risperidone as an effective choice for obsessive-compulsive symptoms and tardive dyskinesia in an Indian quadragenarian with schizo-obsessive disorder. Indian journal of psychiatry. vol 61. issue 3. 2020-02-25. PMID:31142912. |
the authors conclude that risperidone is an effective choice to treat td and comorbid ocs in patients with schizophrenia. |
2020-02-25 |
2023-08-13 |
Not clear |
| Anne Andorn, Jay Graham, John Csernansky, John W Newcomer, Sunita Shinde, Gilbert Muma, Christian Heidbreder, Maurizio Fav. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program. Journal of clinical psychopharmacology. vol 39. issue 5. 2020-01-29. PMID:31343440. |
monthly extended-release risperidone (rbp-7000) in the treatment of schizophrenia: results from the phase 3 program. |
2020-01-29 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iy. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. International clinical psychopharmacology. vol 34. issue 3. 2020-01-23. PMID:30870237. |
metabolism of risperidone by cyp2d6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. |
2020-01-23 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iy. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. International clinical psychopharmacology. vol 34. issue 3. 2020-01-23. PMID:30870237. |
we divided 36 patients with schizophrenia who had undergone treatment mainly with risperidone into two groups: one with normal metabolizing activity of cyp2d6 (n = 15), and the other with lower activity of its variant, cyp2d6*10 (n = 21). |
2020-01-23 |
2023-08-13 |
Not clear |
| Miko Taniguchi, Masakazu Hatano, Hiroyuki Kamei, Risa Inagaki, Shigeki Yamad. Factors That Affect Continuation of Antipsychotic Long-Acting Injections. Biological & pharmaceutical bulletin. vol 42. issue 7. 2019-12-19. PMID:31257286. |
the study population included patients with schizophrenia who were undergoing lai treatment involving risperidone, paliperidone, or aripiprazole at fujita health university hospital between october 2009 and june 2017. |
2019-12-19 |
2023-08-13 |
Not clear |
| Daniel Umbricht, Daniel Javitt, Gerald Novak, John Bates, Simcha Pollack, Jeffrey Lieberman, John Kan. Effects of risperidone on auditory event-related potentials in schizophrenia. The international journal of neuropsychopharmacology. vol 2. issue 4. 2019-11-20. PMID:11285146. |
effects of risperidone on auditory event-related potentials in schizophrenia. |
2019-11-20 |
2023-08-12 |
Not clear |
| R. Cavallaro, P. Mistretta, F. Cocchi, M. Manzato, E. Smerald. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Human psychopharmacology. vol 16. issue 6. 2019-11-20. PMID:12404552. |
differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. |
2019-11-20 |
2023-08-12 |
Not clear |
| Mark Sergi, Michael Green, Clifford Widmark, Christopher Reist, Stephen Erhart, David Braff, Kimmy Kee, Stephen Marder, Jim Mint. Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. The American journal of psychiatry. vol 164. issue 10. 2019-11-20. PMID:22688151. |
method: one hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. |
2019-11-20 |
2023-08-12 |
human |